Anatomy of a Biotech Follow-On: How Larimar Therapeutics Turned an FDA Win Into a $107.6M Raise in 72 Hours

Every figure below comes from Larimar Therapeutics' own SEC filings and press releases: the proposed-offering and pricing announcements, the underlying Form 8-K corporate presentation, and the company's 10-K cash disclosures. Full sources on SEC EDGAR and GlobeNewswire.

Deal snapshot

Why this one, and where the actual deck is

Unlike a fairness-opinion deck, a banker's internal pitch for "should Larimar raise now, and how" isn't public, that work happens behind closed doors between the company and its bankers before a deal ever launches. What is public, and is the closest real analog to that pitch book, is the standing corporate presentation the company and its banks use in every investor meeting, roadshow call, and conference appearance. Larimar refreshes and re-files this deck with the SEC every few months as an exhibit to a Form 8-K, and it's the actual document management and the syndicate would have walked investors through during this raise.

It's genuinely useful because it's the same deck architecture every clinical-stage biotech roadshow deck follows: disease burden and unmet need, mechanism of action, clinical data package, regulatory pathway/timeline, competitive landscape, and a cash-runway slide near the end that, not coincidentally, usually motivates the next raise. If you want to see actual investor-presentation slides, this is the filing worth pulling up: Larimar Therapeutics' Corporate Presentation, filed as an exhibit to Form 8-K on November 10, 2025, on SEC EDGAR.

The setup: a catalyst, then a raise

This is the single most common playbook in biotech ECM, and Larimar ran it almost textbook-perfectly. On February 24, 2026, Larimar announced its lead program, nomlabofusp (for Friedreich's ataxia), had received FDA Breakthrough Therapy Designation, a real regulatory win that typically moves a stock and, more importantly, signals de-risking to institutional biotech investors. On the morning of February 25, 2026, Larimar announced it had commenced a $75 million underwritten public offering. That evening, the deal priced upsized to $100 million, 33% larger than launched.

That sequencing isn't a coincidence. Clinical-stage biotechs are almost always cash-constrained, and the single best time to raise equity is the moment after good news, when the stock is up and investor attention is highest, before the next data readout, which could go the other way. Bankers and CFOs plan for this: positive catalyst, then launch the raise within 24-48 hours to capture the demand while it's hot.

Deal structure: commenced, priced, upsized, what each step means

Step 1, "commenced an underwritten public offering." This is the launch announcement. Note it names a size ($75M) but not a price, that's set later based on investor demand. It also flags a security structure: common stock, and pre-funded warrants "in lieu of common stock to certain investors that so choose."

Why pre-funded warrants exist: some institutional holders (funds with ownership caps, insiders, certain 13G/13D thresholds) can't or don't want to cross a specific percentage-ownership threshold by taking common stock directly. A pre-funded warrant lets them pay almost the full purchase price upfront ($4.9999 of the $5.00, typically) for the right to buy the underlying share later at a nominal $0.0001 strike, economically identical to owning the stock, without immediately showing up as beneficial ownership of common shares. It's a standard accommodation in biotech raises where large, concentrated holders participate.

Step 2, "priced, upsized, $100 million." Same day, the deal priced larger than announced. An upsize is one of the clearest public signals of a well-oversubscribed book, the syndicate had more investor demand at an acceptable price than the original deal size, so the company (with its banks) elected to sell more stock rather than leave demand on the table. This is different from the $75M staying $75M, or worse, being downsized, both of which would signal weak demand.

Step 3, the overallotment option ("greenshoe"). Underwriters got a 30-day option on an extra 3,000,000 shares. This exists so the syndicate can oversell the deal slightly and cover the short with either the option or open-market purchases, a standard stabilization mechanism, not unique to this deal, but worth knowing it's there on every registered follow-on.

Pricing: $5.00 a share, cheap talk or a real discount?

The offering priced at $5.00 per share for 20,000,000 shares. Public biotech follow-ons almost always price at a discount to the last trade, typically in the mid-single-digit percentage range, because investors need an incentive to commit size into a deal rather than just buying in the open market. The discount is effectively the "cost" the company accepts in exchange for certainty: a bought/underwritten deal guarantees the company gets its money, versus the uncertainty of trying to sell stock into the market gradually (an at-the-market, or "ATM," program) over weeks or months.

The syndicate: four tiers is unusually granular

Most large-cap deals (like the Public Storage bond deal) have two tiers: bookrunners and co-managers. Larimar's equity raise had four.

This tiering is typical of small/mid-cap biotech: LifeSci Capital is a healthcare-specialist bank with deep buy-side relationships specifically among biotech-focused funds, exactly the investor base a Friedreich's ataxia rare-disease name needs, while J.P. Morgan and Guggenheim bring balance sheet, larger institutional reach, and credibility with generalist healthcare funds. Layering specialist boutiques underneath bulge-bracket leads is a common way small biotechs get both broad and deep distribution in one deal.

Use of proceeds: what $107.6M actually buys

Per Larimar's own disclosures, net proceeds are earmarked for continued development of nomlabofusp (including the ongoing rolling BLA submission process toward accelerated approval), and working capital and general corporate purposes, including R&D and early commercialization expenses. The company disclosed that, combined with $136.9 million of cash and marketable securities already on the balance sheet as of December 31, 2025, the $107.6 million in net proceeds is expected to fund operations into the second quarter of 2027.

That's the real purpose of a follow-on for a pre-revenue biotech: it's not growth capital in the way a REIT bond deal is, it's runway. Every dollar raised is measured against the burn rate and the distance to the next major value-inflection event, here, the BLA submission and eventual approval decision.

Why investors bought in: the de-risking story

Clinical-stage biotech equity is a binary-outcome asset class, so what a roadshow deck is really selling is a reduction in that binary risk. Regulatory clarity: Breakthrough Therapy Designation, granted the day before this raise launched, plus prior written FDA guidance on the safety database required for the BLA, materially reduces regulatory uncertainty compared to a company still guessing what the FDA wants. A defined, near-term catalyst: a BLA submission under an accelerated approval pathway gives investors a dated event to underwrite toward, rather than an open-ended development timeline. And precedent financings: Larimar had already completed a $65.1 million offering in July 2025, showing a track record of being able to access capital markets repeatedly, which matters to new investors assessing whether the company can keep funding itself to the finish line.

What happened next

The deal closed on schedule on February 27, 2026. By the time Larimar's Q1 2026 filings were public, the company was reporting a stronger cash position and reiterating the runway extension into Q2 2027. The stock continued trading with meaningful volatility in the months after, typical for a clinical-stage name with binary regulatory catalysts still ahead, but the capital raise itself did exactly what it was designed to do: convert a positive regulatory headline into a fully funded runway through the company's next major event.